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Osteoarthritis is characterized by progressive breakdown of articular cartilage. This review summarizes
ﬁndings of the last year, which shed new light on mechanisms and factors involved in cartilage loss.
Evidence is accumulating that the transcription factor hypoxia-inducible factor-2a (HIF-2a) is highly
enhanced in OA cartilage and drives catabolic metalloproteinases, including the pivotal MMP-13. In
addition, HIF-2a suppresses chondrocyte autophagy, herein promoting chondrocyte apoptosis. The
crucial role of MMP-13 is further underlined by reduced OA pathology in MMP-13 deﬁcient mice. An
intriguing mechanism to drive MMP-13 production is activation of the chondrocyte discoidin domain
receptor (DDR-2) receptor through interaction with denuded collagen type II. The latter might occur in
a proteoglycan depleted peri-cellular matrix, where DDR-2 expression is enhanced in OA cartilage and
transgenic suppression attenuates experimental OA. The initiating role of ADAMTS-5 in proteoglycan loss
appears dependent on interaction with the transmembrane proteoglycan syndecan-4, since syndecan-4
deﬁcient mice are less prone to experimental OA and display reduced ADAMTS-5 activity. Both aging and
the osteoarthritis (OA) process itself induce deranged transforming growth factor-b (TGFb)-receptor
expression, causing a shift to dominant usage of the receptor ALK-1, in stead of ALK5 and resulting in
a TGFbmediated catabolic pathway. ALK-1 rather than TGFb is a promising therapeutic target. Finally, the
alarmins S100A8 and 9 have long been considered as markers of inﬂammatory joint destruction, but now
appear to be catabolic mediators.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Hypoxia-inducible factor-2a (HIF-2a) as a novel target
OA is a condition that affects many tissues of the joint. It is now
generally accepted that the activated synovial tissue contributes to
OA cartilage pathology and the same seems to hold for joint asso-
ciated fat pads. The infrapatellar fat pad secretes a range of
inﬂammatory mediators including cytokines and adipokines and
must be considered as yet another tissue source that inﬂuences
cartilage metabolism1.
The present review focuses on recent ﬁndings on OA cartilage
pathology. Publications from the last half-year of 2009 until
September 2010 were searched in Pubmed with attention to
mechanisms of OA cartilage destruction and deranged chondrocyte
function.
HIF-2a was recently identiﬁed as major transcription factor,
highly expressed in human osteoarthritis (OA) cartilage and
experimental murine OA. HIF-2a, encoded by EPAS1 is stronglyW.B. van den Berg, Rheuma-
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s Research Society International. Pinduced by NF-kB signaling and as such downstream of well-
known mediators like IL-1 and TNF, but also downstream of
inﬂammation and mechanical stress. The group of Chun et al
reported on a series of elegant target validation experiments2. They
ﬁrst showed that ectopic adenoviral overexpression of HIF-2a
causes progressive cartilage damage and upregulation of multiple
degradative enzymes, including MMP-13. In addition, cartilage
destruction is enhanced in transgenic mice with chondrocyte-
speciﬁc overexpression of HIF-2a. Ultimate proof of a pivotal role
was provided by genetic deletion of one allele of HIF-2a and
demonstration of suppressed OA pathology in two models of
murine OA, induced by destabilized medial meniscus (DMM) or
collagenase injection, with concomitant reduction of catabolic
factors. In a back to back paper to the above mentioned Nature
Medicine study, the group of Kawaguchi identiﬁed HIF-2a as an
extensive regulator of the endochondral ossiﬁcation process during
OA development3 and herein broadens the involvement of HIF-2a.
It is worthwhile to mention that control of normal homeostasis is
not only dependent of HIF-2a, but also relates to the balancing
activity of HIF-1a, a factor induced by hypoxia and involved in
cartilage formation and maintenance.
With respect to therapeutic targeting of HIF-2a, some caution
seems warranted. Most transcription factors are active in multipleublished by Elsevier Ltd. All rights reserved.
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local targeting of OA affected joints probably is the preferred way
forward. In addition, HIF-2a is primarily expressed in early stages of
OA, so therapy should be started at recent onset of OA. As an aside,
the transcription factor NFAT1 was long recognized to be involved
in T cell activation and osteoclastic bone resorption. A recent study4
identiﬁed OA changes in NFAT1 deﬁcient mice, along with
enhanced expression of degradative enzymes. Forced expression of
NFAT1 with lentiviral vectors rescued normal chondrocyte function
and for this transcription factor therapy should be aimed at
upregulation.
Deranged autophagy
Autophagy is a process for turnover of intracellular organelles
and molecules that protects cells during stress responses. It is now
claimed that autophagy is a protective mechanism in normal
cartilage and its aging-related loss is linked with cell death and OA.
The group of Martin Lotz evaluated the expression of a set of
autophagy related proteins, ULK1, Beclin1 and LC3 in normal and
OA human articular cartilage5. Expression was strongly reduced in
OA chondrocytes, but strikingly high in OA cell clusters. Further
analysis in aging mice showed decreased expression of the
autophagy markers along with proteoglycan loss and this corre-
lated with an increase of the apoptosis marker PARP p85. A similar
pattern was found in surgically induced murine OA.
Intriguingly, an earlier paper of Bohensky et al6 showed that
HIF-2a suppresses chondrocyte autophagy, identifying yet another
role of HIF-2a in OA cartilage pathology. Of interest, reduction of
HIF-2a using siRNA silencing technology enhanced HIF-1a and
underlined the balancing role of this set of HIFs.
MMP-13
MMP-13 or collagenase 3 has long been considered as the major
enzyme involved in OA cartilage erosion. Suggestive evidence was
obtained by transgenic postnatal overexpression of the enzyme in
mice, resulting in focal OA cartilage pathology at load bearing sites7.
Now, ultimate proof of its role is obtained by the demonstration of
reduced OA cartilage erosions in MMP-13 deﬁcient mice8. OA was
surgically induced by DMM and aspects of cartilage pathology were
evaluated at 4 and 8weeks. Erosionswere not different betweenwild
type andMMP-13/mice at 4 weeks, but at 8weeks erosionswere
markedly suppressed in theknockout. Aggrecan losswasalreadyhigh
at 4 weeks in both groups and remained high at 8 weeks. It identiﬁes
that MMP-13 deﬁciency can inhibit cartilage erosion in the presence
of aggrecan depletion, and underlines that aggrecan depletion on its
own does not drive cartilage erosion. Earlier observations showed
that ADAMTS-5 is the pivotal aggrecanase in mice causing aggrecan
breakdown in OA9 and that OA cartilage pathology is reduced in
ADAMTS-5 knockout mice. This implies that aggrecan loss paves the
way for MMP-13 mediated attack of denuded collagen type II. Both
ADAMTS-5andMMP-13 remain interesting therapeutic targets if side
effects on physiology can be limited.
The study in MMP-13 knockout mice further demonstrated that
MMP-13 has no critical role in OA associated osteophyte formation.
Osteophytes developed undisturbed in the absence of MMP-13. The
same holds for chondrocyte hypertrophy as characterized by
collagen type X and positive staining for the aggrecan neoepitope
DIPEN: it does not in itself lead to cartilage erosion.
Discoidin domain receptor (DDR-2)
Given the problems encountered with side effects of MMP-13
targeting it remains of considerable interest to look for targetsupstream of MMP-13. Apart from cytokines and growth factors,
DDR-2 is now considered as such a target. DDR-2 is a cell surface
receptor tyrosine kinase that preferentially interacts with type II
collagen. It is argued that in normal cartilage collagen type II is
coveredwith proteoglycans anddoes not interactwithDDR-2 on the
surface of the chondrocyte. However, when proteoglycan depletion
occurs, denuded CII is recognized and results in chondrocyte MMP-
13 production, along with upregulation of DDR-2 expression which
ampliﬁes the process. In an elegant set of in vivo studies in DDR-2
deﬁcientmice the relevance of thismechanism for OA has nowbeen
demonstrated10. Doubleheterozygousmutantmiceweregenerated,
which are both deﬁcient in type XI collagen and DDR-2. The type XI
deﬁciency drives OA cartilage pathology and this was signiﬁcantly
reduced by DDR-2 deﬁciency, coincident with reduced MMP-13
expression. In addition, the surgical DMMmodelwas induced in the
heterozygous DDR-2 mice and impressive reduction of cartilage
erosions was found as compared to OA pathology in WT mice. The
same group very recently showed acceleration of OA progression by
chondrocyte-speciﬁc overexpression of DDR-2. The latter condition
is also observed in human OA cartilage.
It remains to be explored what local condition really ignites the
erosive DDR-2-CII interaction on the chondrocyte surface. It is
a long-standing observation in het experimental arthritis ﬁeld, that
cartilage can be heavily depleted of proteoglycans for weeks by
sustained local exposure to inﬂammatory stimuli, but this on its
own does not lead to erosions and when inﬂammation wanes the
cartilage proteoglycan content is restored. Apparently, under OA
inducing conditions, like CXI deﬁciency or abnormal load bearing,
the peri-cellular matrix around the chondrocyte is further
disrupted.
Syndecan-4
Apart from induction of enzymes by activated chondrocytes,
their function is further regulated by interaction with matrix
molecules and cell surface proteoglycans. Syndecan-4 is a trans-
membrane heparan sulfate proteoglycan that seems crucial for the
activity of ADAMTS-5. Syndecan-4 is speciﬁcally induced in type X
producing chondrocytes and syndecan-4 immunostaining is
abundant in both human and murine OA cartilage. The group of
Thomas Pap elegantly showed that the loss of Syndecan-4 activity
markedly reduced OA cartilage pathology in the murine DMM OA
model. This was demonstrated both in Syndecan-4 knockouts as
well as in WT mice, locally treated by intraarticular injections with
Syndecan-4 speciﬁc antibodies11. In vitro studies identiﬁed direct
interaction of Syndecan-4 with ADAMTS-5. In addition, it is claimed
that ADAMTS-5 activity is dependent on MMP-3 and the latter
activity is controlled by Syndecan-4.
Potentially, the story is more complex. Matsui et al demon-
strated accelerated development of aging associated and instability
induced OA in osteopontin-deﬁcient mice, characterized by
increased MMP-13 activity12. It identiﬁes a protective role of
osteopontin. Osteopontin is a noncollagenous matrix protein,
originally described in bone but later on also found in hypertrophic
cartilage. It contains an RGD sequence that interacts with integrin
receptors, and its function is negatively regulated by Syndecan-413.
So, osteopontin has a protective role in OA, which is suppressed by
Syndecan-4. Syndecan-4 deﬁciency will unmask osteopontin
activity and this might contribute to the observed reduction of OA
in Syndecan-4 knockouts.
Transforming growth factor-b (TGFb)
TGFb is considered as a crucial anabolic growth factor for



























Fig. 1. Pathways of OA cartilage pathology.
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cause OA like tissue pathology upon sustained exposure in the joint
and it is a pivotal driving force for osteophyte formation14,15. This
dualistic role has long remained enigmatic, but recent insight in
receptor usage has provided further clues. The protective role of
TGFb runs through the ALK5 receptor and the downstream
signaling pathway SMAD2/3, with induction of TIMP, counteraction
of IL-1 and prevention of hypertrophy. In contrast, when TGFb
interacts with the ALK-1 receptor, it signals through SMAD 1,5,8 and
induces degradative enzymes (MMP-13). We recently demon-
strated that there is a shift in receptor usage with aging and during
OA, from the protective ALK5 toward the destructive ALK-116,
implying a dominant pathogenic role of TGFb. It makes ALK-1
a better therapeutic target as compared to TGFb.
The role of the protective SMAD3 pathway is further underlined
by the demonstration of aberrant hypertrophy in SMAD3-deﬁcient
murine chondrocytes, which can be rescued by TGFb e activated
kinase (TAK-1)/activating transcription factor 2 (ATF-2) signaling
and restoration of p38 activation17. Furthermore, genetic variation
in the SMAD3 gene was found to be associated with human hip and
knee OA18.
S100A8/A9
The alarmins S100A8 and A9 have long been considered as
markers of destructive processes in the joint. Previously known as
MRP8 andMRP9 (myeloid related protein) these factors were found
at high levels in synovial ﬂuid, reﬂect leucocyte activity and coin-
cide with progression of joint damage in rheumatoid arthritis. Now
it becomes clear that these alarmins are also mediators of inﬂam-
mation and can signal through TLR419. We have shown that carti-
lage destruction in experimental arthritis is reduced when the
model is induced in S100A8/9 deﬁcient mice20. Furthermore,
expression of these proteins was markedly enhanced in arthritic
cartilage, and in vitro S100A8 shows a direct potency to stimulate
chondrocytes to produceMMPs and to cause aggrecanasemediated
peri-cellular matrix degradation21. A recent study of Zreiqat et al
more extensively explored dose dependent upregulation of various
ADAMTSs and MMPs22 and provided evidence for expression of
S100A8 and A9 in cartilage of early but not late experimental OA.
We recently evaluated the impact of S100A8/9 deﬁciency on the
occurrence of experimental OA. We did not see a phenotype in the
DMM model, but found clear suppression of cartilage pathology in
the collagenase induced instability OA. The latter model is char-
acterized by considerable synovial activation and apparently only
under those conditions synovial S100A8/9 make a signiﬁcant
contribution. The same might hold true in humans, with an
expected role in OA patients with an inﬂammatory phenotype.
Final remarks
This review focused on some major developments in 2010. One
pathway that deserves some attention is the Wnt/b-catenin
signaling, although no major breakthroughs were reported in the
period covered by this paper. Earlier work showed enhanced b-
catenin expression in human OA cartilage and elegant studies in
transgenic mice identiﬁed that conditional, cartilage speciﬁc acti-
vation in adult mice induces an OA like phenotype23. Some recent
reviews are suggested for further reading24,25.
Figure 1 summarizes major elements of the studies discussed
above. It shows multiple pathways of chondrocyte triggering and
downstream transcription factors, with a ﬁnal common pathway of
MMP-13 mediated collagen type II breakdown and ultimate
cartilage erosion. Fine-tuning of ADAMTS-5 activity is under the
control of Syndecan-4 and Osteopontin, with an intermediate roleof MMP-3. The latter is also crucial in MMP-13 activation. Deranged
autophagy causes cell death and impairs regenerative capacity of
the cartilage.
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